Loading...
Probi AB (publ)
PBBIF•PNK
Healthcare
Biotechnology
$24.00
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $15.41M in Q4 2023 to $143.71M in Q3 2024. Gross profit remained healthy with margins at 34% in Q3 2024 compared to 31% in Q4 2023. Operating income hit $3.00M last quarter, sustaining a consistent 2% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $30.23M. Net income dropped to $3.58M, while earnings per share reached $0.31. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan